Dr. Kevin Blase Deandrade, MD

Dr. Deandrade practices at Mobile Heart Specialists in Mobile, Alabama.

Dr. Deandrade's NPI, 1174781017, was assigned on May 28, 2008. Dr. Deandrade attended University of Alabama School of Medicine. Dr. Deandrade holds Alabama license 30054.

Dr. Deandrade's primary practice is Mobile Heart Specialists, at 6701 Airport Blvd, Mobile, AL 36608 in Mobile County. The practice phone is (251) 433-4700.

Dr. Deandrade's primary practice is Mobile Heart Specialists in Mobile, Alabama. Dr. Deandrade is also affiliated with USA Health University Hospital. The medical group on file is USA Health Physician Billing. Dmand AI also links Dr. Deandrade to 2 more hospitals, 4 group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Deandrade practices, 7 sites in all. Vendor and product names are available with a free account.

Interventional cardiology is Dr. Deandrade's primary specialty in the NPI Registry, under taxonomy code 207RI0011X. Dr. Deandrade is board certified in cardiovascular disease by the American Board of Internal Medicine. Dr. Deandrade is licensed in Alabama.

CMS data shows 1,777 Medicare services from Dr. Deandrade across 26 procedure codes in 2024, for 558 Medicare patients. Medicare paid $137,051 for them.

CMS counts 558 Medicare patients who saw Dr. Deandrade in 2024. The largest group is 65 to 74, with 198 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 13% are also on Medicaid. Their average risk score is 1.48, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Deandrade's median patient age at 71, with 54% women.

In 2024, Dr. Deandrade wrote 4,888 Medicare Part D claims for 679 patients. 83% of them were for generic drugs. CMS names the drug for 4,691 of them, across 48 drugs with 11 or more claims each, at $707,175 in total drug cost. In 2023, CMS named 4,188 claims across 48 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Deandrade for performance year 2024, reported as part of a group. Dr. Deandrade accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 21 procedures of coronary angioplasty and stenting by Dr. Deandrade, more than 52% of the clinicians it reports for that procedure.

Leg revascularization (restoring blood flow): 1 to 10 procedures (CMS shows small counts as a range)

Pacemaker insertion or repair: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 2 papers to Dr. Deandrade in 2014. Dr. Deandrade's most frequent co-authors are Nidal Abi Rafeh, MD, Salman Atiq Arain, MD and Andrew Rosslyn Burchett, MD.

CMS Open Payments shows 69 general payments to Dr. Deandrade from 12 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 51% of the total. Penumbra, Inc. paid the most, $2,022.

Dr. Deandrade attended University of Alabama School of Medicine.